“Buoyed by the robust growth of the global biopharmaceutical industry, we set up a R&D service pipeline in the United States, with the aim of developing our platform in two core markets. This way, Genetron Health can not only synchronize its services, but also establish industry benchmarks, facilitating future Sino-U.S. market approvals.”
OFFICER, GENETRON HEALTH
In 2020, Dr. Yunfu Hu (former Deputy Director of the FDA Center for Medical Devices and Radiological Health (CDRH)/Office of In-Vitro Diagnostic and Radiological Health (OIR)) joined Genetron Health as its CMO. During his FDA tenure, Dr. Hu oversaw the approval process for a number of the world’s first companion diagnostic products. His joining in Genetron Health further strengthened our scientific research and product transformation capabilities.
Genetron Health’s diversified platform features innovative patented technologies such as the “One-Step Seq Method” and a nationwide marketing network, enabling our veteran registry team to provide clients with R&D of integrated companion diagnostic products and commercialization services.
Accounting for the full biopharma R&D pipeline, Genetron Health’s one-stop solutions range from clinical trial design consultations to patient recruitment, and from biomarker testing services (CLIA certified, CAP & ISO 15189:2012 accredited laboratory quality control) to subsequent data mining.
Genetron Health’s big data platform enables precision testing for early stage research and targeted screening solutions for patients covered by our biopharma partners. Our team provides industry-leading expertise and support for new drug development and validation.